# Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

> **NCT01527149** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 37 (actual)

## Conditions studied

- Stage I Mantle Cell Lymphoma
- Stage II Contiguous Mantle Cell Lymphoma
- Stage II Non-Contiguous Mantle Cell Lymphoma
- Stage III Mantle Cell Lymphoma
- Stage IV Mantle Cell Lymphoma

## Interventions

- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Dexamethasone
- **DRUG:** Doxorubicin Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Methotrexate
- **BIOLOGICAL:** Ofatumumab
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT01527149
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-06
- **Primary completion:** 2018-04-26
- **Final completion:** 2024-01-11
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2024-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01527149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01527149, "Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT01527149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*